Today, the Dutch cabinet announced the investment of €56 million into the establishment of a “pilot factory” for regenerative therapies. NecstGen and three other facilities will form a chain covering the development and manufacturing of cell therapies, biomaterials, microtissues and macrotissues. The funding is awarded to RegMed XB, a collaboration of research institutes, governments, provinces, health funds, and industry in the Netherlands and Flanders aimed at the development of regenerative therapies and technologies.

Paul Bilars, CEO of NecstGen: “I am very excited about this investment in NecstGen. It will support us in our ambition to advance the development and manufacturing of promising regenerative therapies. We look forward to further strengthen the ecosystem of regenerative medicine in the Netherlands together with our RegMed XB-partners.”

“This pilot factory can focus on an underserved group of therapy developers: academic institutes and small companies.” Sander van Deventer, strategic advisory board member of NecstGen, further adds. “The investment thereby contributes to the continuation of a great pipeline that has been build up in and around the Netherlands”.

NecstGen will be supported by its local partners LUMC, Leiden University and Provincie Zuid-Holland and is currently building its GMP facility at the Leiden Bio Science Park. The company will open its doors in 2022.